

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
07 July 2022 (07.07.2022)



(10) International Publication Number
WO 2022/147537 A1

(51) International Patent Classification:

A61K 31/4174 (2006.01) A61P 25/00 (2006.01)
A61K 9/00 (2006.01) A61P 29/00 (2006.01)

(21) International Application Number:

PCT/US2022/011130

(22) International Filing Date:

04 January 2022 (04.01.2022)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/133,593	04 January 2021 (04.01.2021)	US
63/156,703	04 March 2021 (04.03.2021)	US
63/168,995	31 March 2021 (31.03.2021)	US
63/180,284	27 April 2021 (27.04.2021)	US
63/218,965	07 July 2021 (07.07.2021)	US

(71) Applicant: **BIOXCEL THERAPEUTICS, INC.**
[US/US]; 555 Long Wharf Drive, New Haven, Connecticut
06511 (US).


(72) Inventors: **RISINGER, Robert**; c/o BioXcel Therapeutic, Inc., 555 Long Wharf Drive, New Haven, Connecticut 06511 (US). **SABADOS, Jeffrey R.**; c/o BioXcel Therapeutics, Inc., 555 Long Wharf Drive, New Haven, Connecticut 06511 (US). **ADEDOYIN, Adedayo**; c/o BioXcel Therapeutics, Inc., 555 Long Wharf Drive, New Haven, Connecticut 06511 (US). **RAJACHANDRAN, Lavanya**; c/o BioXcel Therapeutics, Inc., 555 Long Wharf Drive, New Haven, Connecticut 06511 (US).

(74) Agent: **BROWN, Fraser D.** et al.; Cooley LLP, 1299 Pennsylvania Ave., Suite 700, Washington, District of Columbia 20004 (US).

(81) Designated States (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW,

(54) Title: DEXMEDETOMIDINE TREATMENT REGIMENS

FIG. 1 Change in PEC score from baseline in elderly dementia patients until 8 hours post-dose



P values at 0.5 hrs are 0.0295 for Dex 30 mcg and 0.0568 for Dex 60 mcg

Dex = dexmedetomidine; PANSS = Positive and Negative Syndrome Scale; PEC = PANSS Excitatory Component

(57) Abstract: Disclosed herein are methods of administering dexmedetomidine or a pharmaceutically acceptable salt thereof to a human subject. The disclosed methods are particularly suitable for the treatment of agitation, especially when associated with neurodegenerative and/or neuropsychiatric diseases or disorders such as dementia and delirium.

[Continued on next page]

SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— with international search report (Art. 21(3))